FDA Clearance Tracker · P000039-S013
AMPLATZER MULTI-FENESTRATED SEPTAL OCCLUDER ? ?CRIBRIFORM? OCCLUDER
Last checked: Nov 20, 2026Latest source record: Sep 21, 2006 (this decision)Source: openFDAMethods & limitations
Decided
Sep 21, 2006
Approved
Time to decision
304 days
Received Nov 21, 2005. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P000039-S013
- Device name
- AMPLATZER MULTI-FENESTRATED SEPTAL OCCLUDER ? ?CRIBRIFORM? OCCLUDER
- Applicant
- ABBOTT MEDICAL
- Applicant location
- St. Paul, MN
- Received
- Nov 21, 2005
- Decided
- Sep 21, 2006
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P000039
Device type
- Device type
- OCCLUDER, PATENT DUCTUS, ARTERIOSUS (MAE)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE AMPLATZER MULTI-FENESTRATED SEPTAL OCCLUDER (?CRIBRIFORM? OCCLUDER). THE DEVICE IS INDICATED FOR THE CLOSURE OF MULTI-FENESTRATED (CRIBRIFORM) ATRIAL SEPTAL DEFECTS.
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.